✉news BusinessRetail first seen 5 h ago, last 4 h ago, peak #34
Candel Therapeutics Slips Despite Encouraging Prostate Cancer Drug Data
Original: CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’
Candel Therapeutics shares fell even after the company reported encouraging data for its prostate cancer drug candidate. Retail investors are pushing back against the drop, with many calling the stock 'clearly a buy and hold' and arguing the market is overlooking the positive clinical results. The disconnect between the upbeat data and the falling share price is fueling debate among traders about the biotech's prospects.
Why now: Retail investors are discussing the stock because it dropped despite positive clinical trial data, creating a perceived buying opportunity.
Evidence
- CADL Slips Despite Encouraging Prostate Cancer Drug Data — Retail Believes Stock Is ‘Clearly A Buy And Hold’ · Stocktwits
API: https://socialmediatrends-api.osmike.com/v1/trends/513108